ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
HR NBL2: High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
Protocol ID
HR NBL2
Disease (Sub Disease)
Neuroblastoma
Diagnosis Stage
Newly diagnosed
Location
NSW, VIC
Sponsor
Australian & New Zealand Children's Haematology/Oncology Group
Collaborators
Gustave Roussy, Cancer Campus, Grand Paris
Links
External Registry ≫
Trial Status
Open
Sites
John Hunter Children's Hospital
Sydney Children's Hospital
Monash Children's Hospital
Study Type
Treatment
Phase
Phase 3
Age Eligibility
up to 20 years
International registry ID's
NCT04221035
Back to Registry
Study Title HR NBL2: High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
Protocol ID HR NBL2
Disease (Sub Disease) Neuroblastoma
Diagnosis Stage Newly diagnosed
Location NSW / VIC
Sponsor Australian & New Zealand Children's Haematology/Oncology Group
Collaborators Gustave Roussy, Cancer Campus, Grand Paris/
Links https://clinicaltrials.gov/ct2/show/NCT04221035
Trial Status Open
Trial Open Date 31/03/2023
Sites John Hunter Children's Hospital/ Sydney Children's Hospital / Monash Children's Hospital
Study Type Treatment
Phase Phase 3
Age Eligibility up to 20 years
International registry ID's NCT04221035

Join our newsletter

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Email info@anzchog.org   |  

Level 6, TRF Building, Hudson Institute, 27-31 Wright St, Clayton VIC 3168

ANZCHOG acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait Islander cultures, and to Elders both past and present. We acknowledge Māori as tangata whenua of Aotearoa New Zealand and as Treaty partners with the Crown as agreed in Te Tiriti o Waitangi. 

We are committed to creating a safe and welcoming environment that embraces all backgrounds, cultures, sexualities, genders and abilities.